US OptionsDetailed Quotes
ALXO250516C500
- 0.15
- 0.000.00%
15min DelayClose May 5 16:00 ET
0.00High0.00Low
0.15Open0.15Pre Close0 Volume159 Open Interest0.50Strike Price0.00Turnover350.74%IV18.18%PremiumMay 16, 2025Expiry Date0.05Intrinsic Value100Multiplier10DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.6772Delta1.0929Gamma3.67Leverage Ratio-0.0057Theta0.0001Rho2.48Eff Leverage0.0003Vega
ALX Oncology Stock Discussion
Breakthrough: New Lymphoma Treatment Achieves 83% Complete Response Rate, Outperforming Standard Therapy
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
Friday, 25th April at 1:10 pm
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity
- Combination generate...
ALX Oncology's Evorpacept Falls Short in Dual Phase 2 Head and Neck Cancer Trials - What's Next?
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
Friday, 25th April at 9:00 am
In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational study
Company remains confident in continuing to pursue evorpacept in multiple c...
ALX Oncology Receives Ind Clearance From U.S. FDA for Alx2004, a Novel Egfr-Targeted Antibody-Drug Conjugate
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
Monday, 7th April at 8:00 am
• ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors that was created from ALX Oncology's proprietary linker-payload platform
• ALX2004, the company's first ADC, was fully designed and developed in-house by ALX Oncology scientists
• Company expects to in...
No comment yet